Physician profile
Rosemarie Lajara
NPI 1780862102
$1,203,461.36
in general payments reported to CMS, 2019-2025
48 companies · $226K in 2025
The $226K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225K · 2020: $119K · 2021: $155K · 2022: $211K · 2023: $141K · 2024: $126K · 2025: $226K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $249K · Travel and Lodging: $94K · Consulting Fee: $63K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $56K · Food and Beverage: $22K · Honoraria: $9,783 · Gift: $59.40 · Education: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $249,173.81 |
| Travel and Lodging | $93,716.27 |
| Consulting Fee | $63,172.57 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $55,550.00 |
| Food and Beverage | $21,845.34 |
| Honoraria | $9,783.00 |
| Gift | $59.40 |
| Education | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $412,511.33 | 2019-2025 | Jardiance, Mounjaro, Humulin |
| Novo Nordisk INC | $236,026.27 | 2019-2025 | Ozempic, Rybelsus, Victoza |
| Abbott Laboratories | $216,180.83 | 2020-2025 | Freestyle Libre 3, Freestyle Libre, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97,163.35 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $54,872.09 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $54,348.19 | 2019-2025 | |
| Sequel Med Tech, LLC | $31,054.53 | 2024-2025 | Twiist |
| Eli Lilly and Company | $20,503.94 | 2021-2024 | Jardiance |
| Insulet Corporation | $19,303.85 | 2019-2025 | Omnipod, Omnipod |
| Corcept Therapeutics | $15,732.82 | 2019-2025 | Korlym |
| Mannkind Corporation | $13,646.15 | 2019-2025 | V-Go, Afrezza |
| Valeritas, INC. | $11,793.23 | 2019 | |
| Zealand Pharma US, INC. | $5,228.33 | 2020-2022 | |
| Amarin Pharma, INC. | $4,485.05 | 2019-2020 | |
| Ibsa Pharma INC. | $2,189.73 | 2022-2025 | Tirosint, Licart, Flector |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,022.56 | 2022-2024 | Minimed 780g |
| Tandem Diabetes Care, INC. | $1,872.78 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $615.00 | 2022-2025 | Cequr Simplicity |
| Dexcom, INC. | $536.42 | 2019-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $367.62 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Gilead Sciences, INC. | $360.00 | 2020 | |
| Boehringer Ingelheim International Gmbh | $345.00 | 2025 | |
| Merck Sharp & Dohme LLC | $303.01 | 2019-2021 | |
| Grt US Holding, INC. | $246.26 | 2021 | |
| Abbvie INC. | $216.11 | 2021-2024 | |
| Radius Health, INC. | $209.62 | 2022-2025 | Tymlos |
| Amgen INC. | $167.67 | 2019-2025 | Prolia, Evenity, Tepezza |
| Intuity Medical INC | $157.84 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Beta Bionics, INC. | $139.29 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Bayer Healthcare Pharmaceuticals INC. | $134.04 | 2022 | |
| Averitas Pharma INC. | $121.13 | 2023 | Qutenza |
| Avvisto Therapeutics, LLC | $105.14 | 2025 | Cycloset |
| Recordati_rare_diseases_inc. | $57.95 | 2021-2024 | Isturisa, Signifor Lar |
| Companion Medical, INC. | $52.79 | 2020 | |
| Amphastar Pharmaceuticals, INC. | $47.61 | 2024-2025 | |
| Ultragenyx Pharmaceutical INC. | $46.22 | 2021-2022 | |
| Madrigal Pharmaceuticals | $44.61 | 2025 | Rezdiffra |
| Ascendis Pharma Endocrinology INC | $42.71 | 2023 | |
| Ascensia Diabetes Care US INC. | $38.74 | 2021-2024 | |
| Pfizer INC. | $37.82 | 2022-2024 | |
| Itamar Medical INC | $29.83 | 2024 | Watchpatone |
| Verity Pharmaceuticals INC. | $25.78 | 2024 | Tlando |
| Kvk-Tech, INC. | $18.14 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.64 | 2023 | Cycloset |
| Eisai INC. | $12.57 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.03 | 2019 | |
| Medtronic Minimed, INC. | $10.93 | 2019 | |
| Arbor Pharmaceuticals, INC. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosemarie Lajara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.